Treatment of pulmonary hypertension secondary to connective tissue diseases.

  title={Treatment of pulmonary hypertension secondary to connective tissue diseases.},
  author={Olivier Sanchez and Marc Humbert and Olivier Sitbon and G{\'e}rald Simonneau},
  volume={54 3},
Pulmonary hypertension has been identified as one of the well known life threatening complications of connective tissue diseases. In patients with connective tissue diseases pulmonary hypertension occurs with little or no evidence of parenchymal lung disease. As in primary pulmonary hypertension, the pathophysiology is unknown but the clinical course and pathological findings are similar. Scleroderma, particularly in its CREST variant (calcinosis, Raynaud’s phenomenon, oesophageal dysmotility… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 39 extracted citations

Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis

Rheumatology International • 2012
View 14 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 57 references

Survival in pulmonary hypertension associated with connective tissue diseases ( PHCTD ) treated with long - term epoprostenol ( PgI 2 ) : comparison with primary pulmonary hypertension ( PPH )

O Sitbon, M Humbert, O Sanchez
Am J Respir Crit Care Med • 1999

Acute hemodynamic responses to vasodilators in patients with connective tissue diseases and pulmonary hypertension

O Sanchez, O Sitbon, M Humbert
Eur Respir J • 1998

Reduc - tion in pulmonary vascular resistance with long - term epoprostenol ( prostacyclin ) therapy in primary pulmonary hypertension

DE Genthner, MM Panella
N Engl J Med • 1998

Primary pulmonary hypertension.

The New England journal of medicine • 1997

Similar Papers

Loading similar papers…